% | $
Quotes you view appear here for quick access.

Neuralstem, Inc. Message Board

  • here2stayy4ever here2stayy4ever Jun 19, 2013 11:58 AM Flag

    6 out of 15 Trial Patients DIED


    Not good.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • omeg4 Jun 21, 2013 12:38 PM Flag

      Considering the only available drug for ALS increases lifespan by an average of 3-5 months, this is frickin amazing.

    • Those 6 people were already dead. Starting with them was the only way CUR was allowed to proceed. There is no way to spin these results as anything but remarkably positive. If they can repeat this with a larger sample size and cell dose, this will be a paradigm shift in the health care industry. If they can manage their money as well as their science, this will be huge.

      Sentiment: Buy

    • How many in the phase I safety trial showed signs of improvement or stabilization? It's 8 in a safety trial, with a disease that has a 99.9% kill rate. I know of only two people that have lived with ALS for more than three years. Jason Becker, Stephen Hawking.

    • razar1024 Jun 19, 2013 12:31 PM Flag

      You obviously know nothing about ALS.

    • I honestly hope you are an only child and you have no children of your own. Your parents must of had no idea how to raise a child, as you are the #$%$ of the earth. I equate you to a looter. You have no morals, no ethics, no purpose in life except to cheat and decieve people. You are nothing more than a scam artist preying on peoples emotions. You really should be ashamed of yourself but Im sure you hide behind your screen name not caring at all about what clinical trials can do and the sacrifices people make when they sign up for trials like this one .

      Sentiment: Hold

    • ALS kills people, didn't you know that? If you run a trial treating ALS patients with placebos, many will die during the trail. And one patient had a heart problem - prior to the trial - that was the cause of his death. And I believe ALL the deceased patients showed bulbar symptoms prior to the trial. So it appears that the trick for doctors will be to get patients with ALS started on NSI-566 BEFORE they show bulbar symptoms. That's if this early evidence is as indicative of efficacy as it appears to be.

      Sentiment: Strong Buy

0.32+0.01(+3.23%)Sep 23 4:00 PMEDT